Owl Labs Launches Owl 360 Services, Bringing Enterprise Grade Intelligence to Hybrid Meetings
17.6.2026 10:00:00 EEST | Business Wire | Press release
Owl Labs, the leader in 360-degree AI-powered video conferencing and hybrid collaboration technology, today announced Owl 360 Services, its first subscription service built to meet the needs of IT administrators.
As organisations look to support hybrid work with deeper video enablement across more spaces, Owl 360 Services delivers three subscription tiers, offering dedicated support, centralised device management, proactive insights, and warranty coverage scaled to the size and complexity of the deployment.
From launch, every Owl Labs device worldwide, whether newly purchased or already owned, is enrolled in the Core tier at no additional cost, giving all customers built-in analytics from the start. The Enhanced tier, available for direct purchase globally from this summer, adds advanced analytics, dashboards, meeting record history, and API integrations. A premium Enterprise tier, offered exclusively through authorised Owl Labs channel partners, is available now in North America, with advanced analytics, dedicated account management, and four-year warranty coverage. All three tiers provide unique insights, including talk-time insights, meeting duration tracking, visibility into the most frequently used devices and rooms, bulk deployment capabilities, reliable update management, and improved device tracking.
"Owl 360 Services marks a major step forward in how enterprises support and scale hybrid work with Owl Labs," said Frank Weishaupt, CEO of Owl Labs. "As organisations expand their use of Owl Labs technology across more meeting spaces, they need deeper intelligence and more centralised control to keep every room running smoothly. Owl 360 Services brings those capabilities together, helping IT teams support larger fleets, deploy devices at scale, and deliver a consistent, high-quality meeting experience across every space."
With Owl Labs' ease of deployment and real-time visibility into device health, usage, and performance, organisations can maximise uptime, stay ahead of technical issues, and make more informed purchasing decisions. For Owl Labs' channel partners, Owl 360 Services helps customers get more value from every deployment while supporting long-term growth. Owl Labs is also introducing API integrations with the Enhanced tier, connecting to third-party systems and dashboards and unlocking broader data feed capabilities across enterprise environments.
The 360 Services plan tiers include:
- Core: Included at no additional cost with every Owl Labs device globally, whether newly purchased or already owned, Core provides remote management, standard support, and a two-year warranty.
- Enhanced: Available globally for direct purchase from this summer, Enhanced adds advanced analytics, dashboards, meeting record history, and API integrations. Pricing starts at $79 (USD) per device per year with scalable options for larger deployments.
- Enterprise: Designed for larger, business-critical deployments, this tier includes four-year warranty coverage, expedited hardware replacement, on-site spare devices, a dedicated account manager, advanced analytics, dashboards, meeting record history, and priority support. It is available now through authorised Owl Labs channel partners in North America. Pricing starts at $149 (USD) per device annually, paid upfront as a four-year commitment.
The launch builds on Owl Labs' growing momentum as an enterprise-ready platform, including the recent Microsoft Teams certification of the enterprise-grade Meeting Owl 5 Pro device, which completed Owl Labs' full suite of certified peripherals alongside the Meeting Owl 4+, Meeting Owl 3, and Owl Bar. Together, the portfolio gives IT teams confidence that the Owl Labs device ecosystem meets the highest standards for deployment.
To learn more about Owl Labs 360 Services, visit owllabs.com. To find your local reseller, contact sales@owllabs.com.
About Owl Labs
Owl Labs is the first company to build AI-powered, 360-degree video conferencing solutions for hybrid organisations. Its connected device system and Owl Intelligence System™ software make meetings more inclusive and collaborative by levelling the playing field between remote and in-room participants. The Meeting Owl® product line is the first AI-powered, WiFi-enabled, 360-degree camera, microphone and speaker that automatically zooms in on whoever's speaking. Owl Labs has raised $47 million in funding and is based in Boston, with remote and hybrid employees all over the world. To learn more, visit OwlLabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260616664289/en/
Contacts
Louise O’Connell/Megan Hogg | owllabs@clarity.global
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom